Delivery Order HT942523D0011-HT942524F0127
Award Date
7/1/24
Potential Completion Date
6/30/25
Potential Value
$500K
Federal Agency
Defense Health Agency
Awardee
Eitr Biologics, Inc.
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $750,000.00 firm fixed price delivery order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc. for the development of novel nanotherapeutic approaches for the treatment of pneumonic plague. The order is part of a larger $4.39 million Indefinite Delivery Vehicle (IDV) contract between Eitr Biologics and DHA to advance the research and development of nanotherapeutics to combat biological threats. The work will be performed in San Diego, California and involves assessing...
This federal contract award was made by the Defense Health Agency (DHA) to Erivan Bio, LLC, a for-profit limited liability company, for a Small Business Technology Transfer (STTR) Phase I research project titled "Novel Scalable Loading of Antibiotics in Exosomes for Bacterial Wound Infection Prevention". The contract has a firm fixed price of $249,981.86 and a completion date of September 22, 2024. This STTR Phase I award supports research and development to develop a novel approach...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
This federal contract award is for the procurement of medical supplies by the Bureau of Administration, a civilian agency of the U.S. government. The contract was awarded to Biofire Defense LLC, a for-profit limited liability company that specializes in biological threat detection and infectious disease diagnostics, on a firm fixed-price basis. The contract has a ceiling value of $25,000.00 and an ultimate completion date of February 3, 2024. There is no set-aside designation for this...
This federal contract award, valued at $5,008.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order, with a firm fixed price pricing type, and an ultimate completion date of March 11, 2025. The award is not associated with a set-aside designation, indicating open competition. The contract covers the delivery of PRIORIX VIALS, a medical product, to support military...
This is a firm fixed price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency under the Department of Health and Human Services (HHS), to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The $196,434,000 award is for the provision of anthrax antitoxins to treat inhalational anthrax, under the agency's medical countermeasures development and procurement program. The...
This federal contract award from the Defense Threat Reduction Agency (DTRA) to Vitrivax, Inc. is for the optimization and production of single-shot vaccines for melioidosis and glanders. The $29,845,804.71 definitive contract has a cost-plus-fixed-fee pricing type and an ultimate completion date of January 11, 2028. The contract was awarded under a Broad Agency Announcement solicitation that sought innovative research and development projects focused on countering weapons of mass destruction,...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This federal contract award, valued at $43,027,525.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to Hawaii Biotech, Inc. (HBI), a biotechnology company focused on research and development of vaccines and therapeutics for infectious diseases. The contract is for the "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." It is a definitive, cost-plus-fixed-fee contract with a completion date of December 30, 2025....
This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...